JP2017505809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505809A5 JP2017505809A5 JP2016563894A JP2016563894A JP2017505809A5 JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5 JP 2016563894 A JP2016563894 A JP 2016563894A JP 2016563894 A JP2016563894 A JP 2016563894A JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hepe
- free acid
- weight
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926052P | 2014-01-10 | 2014-01-10 | |
| US61/926,052 | 2014-01-10 | ||
| PCT/US2015/011054 WO2015106215A2 (en) | 2014-01-10 | 2015-01-12 | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149177A Division JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505809A JP2017505809A (ja) | 2017-02-23 |
| JP2017505809A5 true JP2017505809A5 (enExample) | 2019-02-14 |
Family
ID=53520398
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563894A Ceased JP2017505809A (ja) | 2014-01-10 | 2015-01-12 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
| JP2019149177A Pending JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149177A Pending JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150196521A1 (enExample) |
| EP (1) | EP3091959A4 (enExample) |
| JP (2) | JP2017505809A (enExample) |
| KR (1) | KR20160132372A (enExample) |
| CN (1) | CN106029051A (enExample) |
| AU (1) | AU2015204531B2 (enExample) |
| BR (1) | BR112016015997A2 (enExample) |
| CA (1) | CA2935986A1 (enExample) |
| IL (1) | IL246623A0 (enExample) |
| MX (1) | MX2016008953A (enExample) |
| PH (1) | PH12016501371A1 (enExample) |
| RU (2) | RU2019110980A (enExample) |
| SG (2) | SG10202000496XA (enExample) |
| WO (1) | WO2015106215A2 (enExample) |
| ZA (1) | ZA201605492B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110478342A (zh) | 2012-05-10 | 2019-11-22 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
| EP3068757B1 (en) | 2013-11-15 | 2019-02-27 | DS Biopharma Limited | Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid |
| JP2018502163A (ja) * | 2015-01-16 | 2018-01-25 | アフィミューン リミテッド | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
| JP2018520197A (ja) * | 2015-07-21 | 2018-07-26 | アフィミューン リミテッド | 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物 |
| WO2017041094A1 (en) | 2015-09-03 | 2017-03-09 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same |
| CN113230244A (zh) | 2015-12-18 | 2021-08-10 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| CN111481550A (zh) * | 2020-05-14 | 2020-08-04 | 王兆霖 | 含有噻托溴铵和阿福特罗的药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| IL151299A0 (en) * | 2000-02-16 | 2003-04-10 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20060160095A1 (en) * | 2002-12-13 | 2006-07-20 | Eirx Therapeutics Limited | Survivin |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| ES2570332T3 (es) * | 2005-03-16 | 2016-05-17 | Meda Pharma Gmbh & Co Kg | La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias |
| WO2012023254A1 (ja) * | 2010-08-19 | 2012-02-23 | 国立大学法人 東京大学 | オメガ３系脂肪酸由来の新規抗炎症性代謝物 |
| WO2012135032A2 (en) * | 2011-03-25 | 2012-10-04 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) * | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| CN110478342A (zh) * | 2012-05-10 | 2019-11-22 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
-
2015
- 2015-01-12 MX MX2016008953A patent/MX2016008953A/es unknown
- 2015-01-12 CA CA2935986A patent/CA2935986A1/en not_active Abandoned
- 2015-01-12 AU AU2015204531A patent/AU2015204531B2/en not_active Ceased
- 2015-01-12 JP JP2016563894A patent/JP2017505809A/ja not_active Ceased
- 2015-01-12 RU RU2019110980A patent/RU2019110980A/ru unknown
- 2015-01-12 SG SG10202000496XA patent/SG10202000496XA/en unknown
- 2015-01-12 RU RU2016132762A patent/RU2685706C2/ru not_active IP Right Cessation
- 2015-01-12 BR BR112016015997A patent/BR112016015997A2/pt not_active Application Discontinuation
- 2015-01-12 CN CN201580008336.5A patent/CN106029051A/zh active Pending
- 2015-01-12 EP EP15735225.3A patent/EP3091959A4/en not_active Withdrawn
- 2015-01-12 KR KR1020167021684A patent/KR20160132372A/ko not_active Withdrawn
- 2015-01-12 SG SG11201605601UA patent/SG11201605601UA/en unknown
- 2015-01-12 WO PCT/US2015/011054 patent/WO2015106215A2/en not_active Ceased
- 2015-01-12 US US14/595,015 patent/US20150196521A1/en not_active Abandoned
-
2016
- 2016-07-06 IL IL246623A patent/IL246623A0/en unknown
- 2016-07-11 PH PH12016501371A patent/PH12016501371A1/en unknown
- 2016-07-22 US US15/217,008 patent/US20160324820A1/en not_active Abandoned
- 2016-08-08 ZA ZA2016/05492A patent/ZA201605492B/en unknown
-
2019
- 2019-08-15 JP JP2019149177A patent/JP2020002150A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505809A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2017509667A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| HRP20192299T1 (hr) | Liječenje nafld i nash | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2017513836A5 (enExample) | ||
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| JP2014218522A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| JP2015155440A5 (enExample) | ||
| JP2017222722A5 (enExample) | ||
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| JP2018538273A5 (enExample) | ||
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2016540015A5 (enExample) | ||
| JP2016530291A5 (enExample) | ||
| JP2016532632A5 (enExample) | ||
| JP2015516419A5 (enExample) |